NasdaqCM - Nasdaq Real Time Price USD

Lixte Biotechnology Holdings, Inc. (LIXT)

Compare
2.0298 -0.0802 (-3.80%)
As of 1:33 PM EDT. Market Open.
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
4,026.1260
5,090.2360
6,311.4810
6,720.4450
3,266.4400
Operating Income
-4,026.1260
-5,090.2360
-6,311.4810
-6,720.4450
-3,266.4400
Net Non Operating Interest Income Expense
-6.9150
1.2530
2.3200
-6.7880
0.6680
Other Income Expense
-0.2150
1.9540
-3.3740
-1.1630
0.8900
Pretax Income
-4,033.2560
-5,087.0290
-6,312.5350
-6,728.3960
-3,264.8820
Net Income Common Stockholders
-4,033.2560
-5,087.0290
-6,312.5350
-6,728.3960
-3,264.8820
Diluted NI Available to Com Stockholders
-4,033.2560
-5,087.0290
-6,312.5350
-6,728.3960
-3,264.8820
Basic EPS
-1.72
-2.66
-3.99
-5.00
-2.90
Diluted EPS
-1.72
-2.66
-3.99
-5.00
-2.90
Basic Average Shares
2,207.7440
1,915.8380
1,582.0290
1,347.3830
1,127.7120
Diluted Average Shares
2,207.7440
1,915.8380
1,582.0290
1,347.3830
1,127.7120
Total Operating Income as Reported
-4,026.1260
-5,090.2360
-6,311.4810
-6,720.4450
-3,266.4400
Total Expenses
4,026.1260
5,090.2360
6,311.4810
6,720.4450
3,266.4400
Net Income from Continuing & Discontinued Operation
-4,033.2560
-5,087.0290
-6,312.5350
-6,728.3960
-3,264.8820
Normalized Income
-4,033.0410
-5,088.9830
-6,309.1610
-6,727.2330
-3,265.7720
Interest Income
14.8490
17.4860
11.1950
0.6260
4.3420
Interest Expense
21.7640
16.2330
8.8750
7.4140
3.6740
Net Interest Income
-6.9150
1.2530
2.3200
-6.7880
0.6680
EBIT
-4,011.4920
-5,070.7960
-6,303.6600
-6,720.9820
-3,261.2080
EBITDA
-4,011.4920
-5,070.7960
-6,303.6600
-6,720.9820
-3,261.2080
Net Income from Continuing Operation Net Minority Interest
-4,033.2560
-5,087.0290
-6,312.5350
-6,728.3960
-3,264.8820
Total Unusual Items Excluding Goodwill
-0.2150
1.9540
-3.3740
-1.1630
0.8900
Total Unusual Items
-0.2150
1.9540
-3.3740
-1.1630
0.8900
Normalized EBITDA
-4,011.2770
-5,072.7500
-6,300.2860
-6,719.8190
-3,262.0980
12/31/2020 - 10/25/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers